(RMD) ResMed - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7611521078
Stock: Sleep Devices, Software, Health Records
Total Rating 57
Risk 96
Buy Signal 0.06
| Risk 5d forecast | |
|---|---|
| Volatility | 32.7% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | -3.39 |
| Character TTM | |
|---|---|
| Beta | 0.780 |
| Beta Downside | 0.388 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.87% |
| CAGR/Max DD | 0.17 |
EPS (Earnings per Share)
Revenue
Description: RMD ResMed March 04, 2026
ResMed Inc. develops and distributes medical devices and cloud-based software for respiratory disorders. The company operates in two segments: Sleep and Breathing Health, and Residential Care Software. This dual focus allows ResMed to address both direct patient care and the administrative needs of healthcare providers. The medical device sector is characterized by ongoing innovation and regulatory oversight.
In its Sleep and Breathing Health segment, ResMed offers diagnostic devices like ApneaLink Air and NightOwl for sleep apnea. It also provides cloud-based platforms such as AirView for remote patient monitoring and myAir for patient engagement. These digital health solutions are increasingly important in chronic disease management, enhancing adherence and data collection.
The Residential Care Software segment includes solutions like Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN. These platforms offer electronic health records, billing services, and analytics for various post-acute care settings. The healthcare software market is experiencing growth driven by demand for efficiency and data-driven decision-making.
For more detailed financial analysis, consider exploring ResMeds performance on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 1.59 > 1.0 |
| NWC/Revenue: 47.62% < 20% (prev 40.27%; Δ 7.35% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.91b > Net Income 1.49b |
| Net Debt (-415.2m) to EBITDA (2.07b): -0.20 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (147.0m) vs 12m ago -0.38% < -2% |
| Gross Margin: 60.98% > 18% (prev 0.58%; Δ 6040 % > 0.5%) |
| Asset Turnover: 69.01% > 50% (prev 68.99%; Δ 0.02% > 0%) |
| Interest Coverage Ratio: 71.47 > 6 (EBITDA TTM 2.07b / Interest Expense TTM 25.7m) |
Altman Z'' 9.29
| A: 0.30 (Total Current Assets 3.82b - Total Current Liabilities 1.25b) / Total Assets 8.50b |
| B: 0.78 (Retained Earnings 6.65b / Total Assets 8.50b) |
| C: 0.23 (EBIT TTM 1.84b / Avg Total Assets 7.82b) |
| D: 3.03 (Book Value of Equity 6.62b / Total Liabilities 2.18b) |
| Altman-Z'' Score: 9.29 = AAA |
Beneish M -3.16
| DSRI: 0.94 (Receivables 985.6m/959.8m, Revenue 5.40b/4.93b) |
| GMI: 0.95 (GM 60.98% / 57.94%) |
| AQI: 0.91 (AQ_t 0.47 / AQ_t-1 0.51) |
| SGI: 1.10 (Revenue 5.40b / 4.93b) |
| TATA: -0.05 (NI 1.49b - CFO 1.91b) / TA 8.50b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of RMD shares?
As of March 05, 2026, the stock is trading at USD 259.05 with a total of 506,453 shares traded.
Over the past week, the price has changed by +2.58%, over one month by -1.28%, over three months by +3.24% and over the past year by +12.92%.
Over the past week, the price has changed by +2.58%, over one month by -1.28%, over three months by +3.24% and over the past year by +12.92%.
Is RMD a buy, sell or hold?
ResMed has received a consensus analysts rating of 3.95.
Therefore, it is recommended to buy RMD.
- StrongBuy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the RMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 297.5 | 14.8% |
| Analysts Target Price | 297.5 | 14.8% |
RMD Fundamental Data Overview February 28, 2026
P/E Trailing = 25.4515
P/E Forward = 25.9067
P/S = 6.951
P/B = 6.7651
P/EG = 1.8635
Revenue TTM = 5.40b USD
EBIT TTM = 1.84b USD
EBITDA TTM = 2.07b USD
Long Term Debt = 403.9m USD (from longTermDebt, last quarter)
Short Term Debt = 289.7m USD (from shortTermDebt, last quarter)
Debt = 1.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -415.2m USD (from netDebt column, last quarter)
Enterprise Value = 37.11b USD (37.52b + Debt 1.00b - CCE 1.42b)
Interest Coverage Ratio = 71.47 (Ebit TTM 1.84b / Interest Expense TTM 25.7m)
EV/FCF = 20.75x (Enterprise Value 37.11b / FCF TTM 1.79b)
FCF Yield = 4.82% (FCF TTM 1.79b / Enterprise Value 37.11b)
FCF Margin = 33.13% (FCF TTM 1.79b / Revenue TTM 5.40b)
Net Margin = 27.53% (Net Income TTM 1.49b / Revenue TTM 5.40b)
Gross Margin = 60.98% ((Revenue TTM 5.40b - Cost of Revenue TTM 2.11b) / Revenue TTM)
Gross Margin QoQ = 62.18% (prev 61.46%)
Tobins Q-Ratio = 4.36 (Enterprise Value 37.11b / Total Assets 8.50b)
Interest Expense / Debt = 0.79% (Interest Expense 7.95m / Debt 1.00b)
Taxrate = 20.87% (103.6m / 496.1m)
NOPAT = 1.45b (EBIT 1.84b * (1 - 20.87%))
Current Ratio = 3.06 (Total Current Assets 3.82b / Total Current Liabilities 1.25b)
Debt / Equity = 0.16 (Debt 1.00b / totalStockholderEquity, last quarter 6.32b)
Debt / EBITDA = -0.20 (Net Debt -415.2m / EBITDA 2.07b)
Debt / FCF = -0.23 (Net Debt -415.2m / FCF TTM 1.79b)
Total Stockholder Equity = 5.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.00% (Net Income 1.49b / Total Assets 8.50b)
RoE = 24.81% (Net Income TTM 1.49b / Total Stockholder Equity 5.99b)
RoCE = 28.71% (EBIT 1.84b / Capital Employed (Equity 5.99b + L.T.Debt 403.9m))
RoIC = 21.82% (NOPAT 1.45b / Invested Capital 6.66b)
WACC = 8.58% (E(37.52b)/V(38.52b) * Re(8.79%) + D(1.00b)/V(38.52b) * Rd(0.79%) * (1-Tc(0.21)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.17%
[DCF] Terminal Value 79.40% ; FCFF base≈1.63b ; Y1≈2.01b ; Y5≈3.42b
[DCF] Fair Price = 358.1 (EV 51.75b - Net Debt -415.2m = Equity 52.16b / Shares 145.7m; r=8.58% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 96.31 | EPS CAGR: 22.32% | SUE: 1.21 | # QB: 1
Revenue Correlation: 96.75 | Revenue CAGR: 14.21% | SUE: 1.78 | # QB: 1
EPS current Year (2026-06-30): EPS=11.03 | Chg7d=+0.000 | Chg30d=+0.124 | Revisions Net=+12 | Growth EPS=+15.5% | Growth Revenue=+9.7%
EPS next Year (2027-06-30): EPS=12.18 | Chg7d=+0.000 | Chg30d=+0.151 | Revisions Net=+16 | Growth EPS=+10.4% | Growth Revenue=+7.5%
[Analyst] Revisions Ratio: +0.67 (15 Up / 3 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 8.8% - Earnings Yield 3.9%)
[Growth] Growth Spread = +2.6% (Analyst 7.5% - Implied 4.9%)
P/E Forward = 25.9067
P/S = 6.951
P/B = 6.7651
P/EG = 1.8635
Revenue TTM = 5.40b USD
EBIT TTM = 1.84b USD
EBITDA TTM = 2.07b USD
Long Term Debt = 403.9m USD (from longTermDebt, last quarter)
Short Term Debt = 289.7m USD (from shortTermDebt, last quarter)
Debt = 1.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -415.2m USD (from netDebt column, last quarter)
Enterprise Value = 37.11b USD (37.52b + Debt 1.00b - CCE 1.42b)
Interest Coverage Ratio = 71.47 (Ebit TTM 1.84b / Interest Expense TTM 25.7m)
EV/FCF = 20.75x (Enterprise Value 37.11b / FCF TTM 1.79b)
FCF Yield = 4.82% (FCF TTM 1.79b / Enterprise Value 37.11b)
FCF Margin = 33.13% (FCF TTM 1.79b / Revenue TTM 5.40b)
Net Margin = 27.53% (Net Income TTM 1.49b / Revenue TTM 5.40b)
Gross Margin = 60.98% ((Revenue TTM 5.40b - Cost of Revenue TTM 2.11b) / Revenue TTM)
Gross Margin QoQ = 62.18% (prev 61.46%)
Tobins Q-Ratio = 4.36 (Enterprise Value 37.11b / Total Assets 8.50b)
Interest Expense / Debt = 0.79% (Interest Expense 7.95m / Debt 1.00b)
Taxrate = 20.87% (103.6m / 496.1m)
NOPAT = 1.45b (EBIT 1.84b * (1 - 20.87%))
Current Ratio = 3.06 (Total Current Assets 3.82b / Total Current Liabilities 1.25b)
Debt / Equity = 0.16 (Debt 1.00b / totalStockholderEquity, last quarter 6.32b)
Debt / EBITDA = -0.20 (Net Debt -415.2m / EBITDA 2.07b)
Debt / FCF = -0.23 (Net Debt -415.2m / FCF TTM 1.79b)
Total Stockholder Equity = 5.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.00% (Net Income 1.49b / Total Assets 8.50b)
RoE = 24.81% (Net Income TTM 1.49b / Total Stockholder Equity 5.99b)
RoCE = 28.71% (EBIT 1.84b / Capital Employed (Equity 5.99b + L.T.Debt 403.9m))
RoIC = 21.82% (NOPAT 1.45b / Invested Capital 6.66b)
WACC = 8.58% (E(37.52b)/V(38.52b) * Re(8.79%) + D(1.00b)/V(38.52b) * Rd(0.79%) * (1-Tc(0.21)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.17%
[DCF] Terminal Value 79.40% ; FCFF base≈1.63b ; Y1≈2.01b ; Y5≈3.42b
[DCF] Fair Price = 358.1 (EV 51.75b - Net Debt -415.2m = Equity 52.16b / Shares 145.7m; r=8.58% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 96.31 | EPS CAGR: 22.32% | SUE: 1.21 | # QB: 1
Revenue Correlation: 96.75 | Revenue CAGR: 14.21% | SUE: 1.78 | # QB: 1
EPS current Year (2026-06-30): EPS=11.03 | Chg7d=+0.000 | Chg30d=+0.124 | Revisions Net=+12 | Growth EPS=+15.5% | Growth Revenue=+9.7%
EPS next Year (2027-06-30): EPS=12.18 | Chg7d=+0.000 | Chg30d=+0.151 | Revisions Net=+16 | Growth EPS=+10.4% | Growth Revenue=+7.5%
[Analyst] Revisions Ratio: +0.67 (15 Up / 3 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 8.8% - Earnings Yield 3.9%)
[Growth] Growth Spread = +2.6% (Analyst 7.5% - Implied 4.9%)